Safety profile of antituberculosis drugs
DOI:
https://doi.org/10.52692/1857-0011.2023.3-77.39Keywords:
antituberculosis drugs, side effects, hepatotoxicity, neurotoxicity, isoniazid, rifampicin, linezolidAbstract
Studying the safety profile of antituberculosis drugs is a priority for the development of a treatment regimen as efficient as possible and with a high degree of tolerability for patients. The development of side adverse reactions of antituberculosis drugs continues to remain one of the main causes of low compliance or even abandonment of the administered treatment. The detection, reporting and analysis of adverse effects associated with the administration of antituberculosis drugs, both for first-line and second-line drugs, serves as a guarantee of successful treatment.
References
Arbex M., de Castro Lima Varella M., de Siqueira H., de Mello FAF. Anti-tuberculosis drugs: drug interactions, adverse effects, and use in special situations. Part 1: first-line drugs. J Bras Pneumol. 2010;36:626-640.
Athira B., Manju C., Jyothi E. A study on adverse drug reactions to first line antitubercular drugs in DOTS therapy. International Journal of Pharmacology and Clinical Sciences. 2015;4(1):7–11.
Bacinschi N., Alexandru S., Donica A., Nepoliuc L., Ceban S., Crivenco L. Hepatotoxicitatea preparatelor antituberculoase. Revistă ştiinţifico-practică Sănătate publică, Economie şi Management în medicină. 2020; 1(83), p.12.
Baghaei P., Tabarsi P., Chitsaz E., et al. Incidence, clinical and epidemiological risk factors, and outcome of drug-induced hepatitis due to anti-tuberculous agents in new tuberculosis cases. Am J Therapeut. 2010;17:17-22.
Baghaei P., Tabarsi P., Dorriz D., et al. Adverse effects of MDRTB treatment with a standardized regimen: a report from Iran. Am J Therapeut. 2011;18:p.29-34.
Carroll M., Lee M., Cai Y., et al. Frequency of adverse reactions to firstand second-line anti-tuberculosis chemotherapy in a Korean cohort. Int J Tuberc Lung Dis. -2012;167:961-966.
Chhetri A., Saha A., Verma S., Palaian S., Mishra P., Shankar P. A study of adverse drug reactions caused by first line anti-tubercular drugs used in Directly Observed Treatment, Short course (DOTS) therapy in western Nepal, Pokharan. J Pak Med Assoc. 2008;58:531-536.
Diacon A., Pym A., Grobusch M. et al. Multidrug-resistant tuberculosis and culture conversion with bedaquiline. N Engl J Med. 2014;371:723-732.
Garg R., Gupta V., Mehra S., Singh R., Prasad R. Rifampicin induced thrombocytopenia. Indian J Tuberc. 2007;54:94-96.
Garg R., Verma S., Mahajan V., Prasad R. Exfoliative dermatitis secondary to ethambutol and pyrazinamide. Internet J Pulm Med. 2008;9:1.
Gerdan G., Nurullah A., Ucan E., Bulac Kir S. Paradoxical increase inuricacid level with allopurinol use inpyrazinamideinduced hyperuricemia. Singap Med J. 2013;54:p.125-128.
Jeong I., Park JS., Cho YJ. et al. Drug-induced hepatotoxicity of anti-tuberculosis drugs and their serum levels. J Korean Med Sci. 2015 Feb;30(2):167-72.
Kang BH., Jo KW., Shim TS. Current status of fluoroquinolone use for treatment of tuberculosis in a tertiary care hospital Korea. Tuberc Respir Dis (Seoul). 2017;80:143-152.
Kant S., Verma SK., Gupta V., Anand SC., Prasad R. Pyrazinamide induced thrombocytopenia. Indian J Pharmacol.2010;42:108-109.
Khalili H. Dashti-Khaviadaki S., Rasolinejad M. et al. Anti-tuberculosis drugs related hepatotoxicity; incidence, risk factors, pattern of changes in liver enzymes and outcome. Daru. 2009, v.17, N.3, p.163-167.
Kurniawati F., Sulaiman SAS., Gillani SW. Adverse drug reactions of primary anti-tuberculosis drugs among tuberculosis patients treated in chest clinic. International Journal of Pharmacy and Life Sciences. 2012;3(1):1331–1338.
Lv X., Tang S., Xia Y., et al. Adverse reactions due to directly observed treatment strategy therapy in Chinese tuberculosis patients: a prospective study. PLoS One. 2013;8, p.65037.
Potter JL., Capstick T., Ricketts WM., Whitehead N., Kon OM. AUK-based resource to support the monitoring and safe use of anti-tuberculosis drugs and second-line treatment of multidrug-resistant tuberculosis. TB Drug Monographs. 2015:90-96.
Prasad R., Singh A., Srivastava R., et al. Adverse drug reaction in the treatment of multi drug resistant tuberculosis. Indian J Tuberc. 2016;63:106-114.
Ramappa V., Aithal G.P. Hepatotoxicity Related to Anti-tuberculosis Drugs: Mechanisms and Management. Clin Exp Hepatol. 2013, Mar; 3(1): 37–49.
Richardson M. et al. Influence of genetic variants on toxicity to anti-tubercular agents: a systematic review meta-analysis (protocol). Systematic Review. 2017, 6, p. 142.
Sarin R., Behera D., Khanna A., Singh V., Narang P., Deepak TS. Second-line injectable induced ototoxicity in drug resistant tuberculosis: a systematic review of Indian studies. Indian J Tuberc. 2019;66:279-287.
Schnippel K., Firnhaber C., Berhanu R., Page-Shipp L., Sinanovic E. Adverse drug reactions during drug-resistant TB treatment in high HIV prevalence settings: a systematic review and meta-analysis. J Antimicrob Chemother. 2017;72:1871-1879.
Shinde KM., Pore SM., Bapat TR. Adverse reactions to first-line anti-tuberculous agents in hospitalised patients: pattern, causality, severity and risk factors. Indian J Med Specialities. 2013;4:1-4.
Singh A., Prasad R., Balasubramanian V., Gupta N., Gupta P. Prevalence of adverse drug reaction with first-line drugs among patients treated for pulmonary tuberculosis. Clinical Epidemiology and Global Health. 2015;3:80–90.
Sinha K., Marak IT., Singh W. Adverse drug reactions in tuberculosis patients due to directly observed treatment strategy therapy: experience at an outpatient clinic of a teaching hospital in the city of Imphal, Manipur, India. The Journal of Association of Chest Physicians. 2013;1(2):50.
Tang S., Yao L., Hao X., et al. Efficacy, safety and tolerability of linezolid for the treatment of XDR-TB: a study in China. Eur Respir J. 2015;45:161-170.
Tawanda G. Chemotherapy of Tuberculosis, mycobacterium Avium Complex Disease and Leprosy. Goodman and Gilman’s the Pharmacological Basis of the Therapeutics. 12th ed. McGraw Hill Med; 2011:1559.
Vedove CD., Del Giglio M., Schena D., Girolomoni G. Drug induced lupus erythematosus. Arch Dermatol Res. 2009;301:99-105.
Verma R., Mahor GR., Shrivastava AR., Pathak P. Adverse drug reactions associated with first-line anti-tubercular drugs in a tertiary care hospital of Central India: a study of clinical presentations, causality and severity. Asian J Pharm Clin Res. 2014;7(5):140–143.
World Health Organisation. Global tuberculosis report 2016. Geneva, Switzerland: WHO; 2016/CDS/ TB/2016.8.
World Health Organization. Global Tuberculosis Report 2018. Geneva: WHO; 2018/CDS/TB/2018.20.
World Health Organization. WHO Consolidated Guidelines on Drug-Resistant Tuberculosis Treatment. Geneva: WHO; 2019 (WHO/CDS/TB/2019.7)
Wu S., Zhang Y., Sun F., et al. Adverse events associated with the treatment of multidrug-resistant tuberculosis: a systematic review and meta-analysis. Am J Therapeut.2016;23:p.521-530.
Yakar F., Yildiz N., Yakar A., Kilicaslan Z. Isoniazid-and rifampicin-induced thrombocytopenia. Multidiscip Respir Med. 2013;8:13.
Yang TW., Park HO., Jang HN., et al. Side effects associated with the treatment of multidrug-resistant tuberculosis at a tuberculosis referral hospital in South Korea: a retrospective study. Medicine (Baltimore). 2017;96, p.7482.
Вольф С. Б. Нежелательные побочные реакции на химиотерапию туберкулеза. Журнал Гродненского государственного медицинского университета. 2016; 3, с.141-146.
Downloads
Published
License
Copyright (c) 2024 Bulletin of the Academy of Sciences of Moldova. Medical Sciences
This work is licensed under a Creative Commons Attribution 4.0 International License.
